Paul Tesar, PhD at Case Western Reserve School of Medicine has discovered a technique that directly converts skin cells to the type of brain cells destroyed in patients with multiple sclerosis, cerebral palsy and other so-called myelin disorders. This discovery appears in the journal Nature Biotechnology. Read more
Online registration for MSC 2013: Adult Stem Cell Therapy and Regenerative Medicine is open and poster abstracts are being accepted for presentation both in poster format and potentially for podium presentation during the main program as well. MSC 2013 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. The breadth of topics from basic discovery through model validation, clinical product development, and therapeutic application, in addition to the links between academic and commercial labs, make this conference imperative for industrial researchers, academic investigators, IP and regulatory specialists, biotechnology development investors and post-doctoral and graduate students.
Learn about stem cells!
Join over 8 million users and learn about how stem cells are being used in the laboratory and in the hospital. The NCRM teamed up with Edheads, a provider of online education tools, to launch 3 web-based education modules about stem cells. The modules, based on real clinical trials, are geared toward high school students and designed to enhance classroom curriculum. They offer a highly innovative and interactive learning experience to demonstrate the nature of stem cells and their importance in medicine and the development of new therapies.
The Ohio Third Frontier Commission unanimously awarded Case Western Reserve University National Center for Regenerative Medicine (NCRM), $2.4 million for its OH-Alive Innovator Platform: A Process and Manufacturing Platform for Cell Therapy. These funds must be matched by NCRM and its collaborators so this represents a total investment of $4.8 million. The OH-Alive platform will help advance Ohio as one of the leading regions for stem cell therapy in the country by establishing a facility that will provide expertise in determining optimized conditions for producing stem cells for therapeutic purposes. Read more
News
May 06, 2013
Stem cells found to cure epilepsy in mice Link to article
April 12, 2013
“First-in-humans” trial with cardiopoietic stem cells shows promising results Link to article
April 01, 2013
Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden Link to article
March 28, 2013
Multi-million-dollar stem cell bank will be based at Buck Institute in Novato Link to article
March 28, 2013
ReNeuron signs 'landmark' pact to advance stem cell line Link to article
May 06, 2013
New material system permits 3-D patterning to regulate stem cell behavior Link to article
April 14, 2013
Ordinary skin cells morphed into functional brain cells Link to article
March 21, 2013
National Center for Regenerative Medicine has 3 of the Top 50 Stem Cell Influencers Link to article
March 12, 2013
Stem cell company Athersys expects more R&D spending, potential partnerships in 2013 Read more: http://medcitynews.com/2013/03/stem-cell-company-athersys-expects-more-rd-spending-potential-partnerships-in-2013/#ixzz2PKtn1VxR Link to article
February 28, 2013
Small Companies Are Hubs of Future Profit in Regenerative Medicine: Gil Van Bokkelen Link to article
The National Center for Regenerative Medicine (NCRM) builds upon leading research and clinical programs at its founding institutions—Case Western Reserve University (CWRU), Cleveland Clinic (CC), and University Hospitals Case Medical Center (UHCMC)—in heart disease, cancer, genetic disorders, wound healing, and immunological, musculoskeletal, and neurodegenerative diseases. The combination of a 26-year history of research on adult and pluripotent stem cells, outstanding clinical and research programs, and tested and proven experience of using adult stem cell transplantation to treat patients makes this Center unique in the United States.
Regenerative medicine represents a new form of medicine using stem cells and tissue engineered scaffolds to generate new tissue in diseased or damaged organs--rather than using drugs or devices to improve function and quality of life.
The NCRM is made up of two organizations--the Center for Stem Cell and Regenerative Medicine (CSCRM) and the Clinical Tissue Engineering Center (CTEC). Through investment by the State of Ohio’s Third Frontier Initiative, $44.5 million in funding has been received since 2003 to commercialize stem cell and tissue engineering therapies. $6.6 million in Federal appropriations has strengthened or created nearly 40 multi-institutional core facilities for Center members to access advanced regenerative medicine equipment and accelerate their research and clinical pursuits.
The broad-based excellence of its partner institutions provides the NCRM a comprehensive approach, including basic and clinical research, biomedical and tissue engineering, and the development and administration of new therapies to patients with cancer as well as cardiovascular, blood, bone, immunological and nervous system diseases. The Center seeks to translate innovative laboratory research into the clinical and commercial arenas to replace and repair diseased tissues and organs. NCRM and its partner institutions and affiliated programs provide educational opportunities that enable nurses, graduate students, and technicians to gain the complex skills required to perform ground-breaking research and deliver optimal patient care in this new field. These efforts help create a well-trained workforce for the Center, for new businesses, and for other institutions.
